Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

It’s All About Abecma As 2seventy Sells Off Pipeline To Regeneron In Restructuring

Jan 30 2024

• By Alaric DeArment

• Source: Shutterstock

Related Content

Regeneron And Bluebird Team Up In Cell Therapy "Joint Venture"-Style Deal

Aug 06 2018

Can Regeneron’s Odronextamab Stand Out With Better Safety?

Dec 11 2023

Regeneron Expands Bispecifics, Gene Therapy Programs As Exec Hints At More Deals

Nov 02 2023

Bluebird Spinoff 2seventy Bio Gets Its Own Wings

Oct 19 2021

2Seventy Cuts Jobs As It Streamlines Pipeline, Focuses On Abecma

Sep 12 2023

As 2024 Begins, US FDA’s Novel Agent Prospects Look A Lot Like 2023

Jan 30 2024

Related Companies

2seventy Bio, Inc.

Regeneron Pharmaceuticals, Inc.

Johnson & Johnson

Legend Biotech Corp.

Additional Topics

Deals Restructuring ImmunoOncology Commercial BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.